Show simple item record

dc.contributor.authorVedaa, Øystein
dc.contributor.authorKallestad, Håvard
dc.contributor.authorScott, Janine Linda
dc.contributor.authorSmith, Otto Robert Frans
dc.contributor.authorPallesen, Ståle
dc.contributor.authorMorken, Gunnar
dc.contributor.authorLangsrud, Knut
dc.contributor.authorGehrman, Philip
dc.contributor.authorThorndike, Frances P.
dc.contributor.authorRitterband, Lee M.
dc.contributor.authorHarvey, Allison G.
dc.contributor.authorStiles, Tore C
dc.contributor.authorSivertsen, Børge
dc.PublishedThe Lancet Digital Health. 2020, 2 (8), E397-E406.
dc.description.abstractBackground Although several large-scale randomised controlled trials have shown the efficacy of digital cognitive behavioural therapy for insomnia (dCBT-I), there is a need to validate widespread dissemination of dCBT-I using recommended key outcomes for insomnia. We investigated the effect of a fully automated dCBT-I programme on insomnia severity, sleep–wake patterns, sleep medication use, and daytime impairment. Methods We did a parallel-group superiority randomised controlled trial comparing dCBT-I with online patient education about sleep. The interventions were available through a free-to-access website, publicised throughout Norway, which incorporated automated screening, informed consent, and randomisation procedures, as well as outcome assessments. Adults (age ≥18 years) who had regular internet access and scored 12 or higher on the Insomnia Severity Index (ISI) were eligible for inclusion, and were allocated (1:1) to receive dCBT-I (consisting of six core interactive sessions to be completed over 9 weeks) or patient education (control group). Participants were masked to group assignment and had no contact with researchers during the intervention period. The primary outcome was the change in ISI score from baseline to 9-week follow-up, assessed in the intention-to-treat population. This trial is registered with (NCT02558647) and is ongoing, with 2-year follow-up assessments planned. Findings Between Feb 26, 2016, and July 1, 2018, 5349 individuals commenced the online screening process, of which 1497 were ineligible or declined to participate, 2131 discontinued the screening process, and 1721 were randomly allocated (868 to receive dCBT-I and 853 to receive patient education). At 9-week follow-up, 584 (67%) participants in the dCBT-I group and 534 (63%) in the patient education group completed the ISI assessment. The latent growth model showed that participants in the dCBT-I group had a significantly greater reduction in ISI scores from baseline (mean score 19·2 [SD 3·9]) to 9-week follow-up (10·4 [6·2]) than those in the patient education group (from 19·6 [4·0] to 15·2 [5·3]; estimated mean difference −4·7 (95% CI −5·4 to −4·1; Cohen's d −1·21; p<0·001). Compared with patient education, the number needed to treat with dCBT-I was 2·7 (95% CI 2·4 to 3·2) for treatment response (ISI score reduction ≥8) and 3·2 (2·8 to 3·8) for insomnia remission (ISI score <8). No adverse events were reported to the trial team. Interpretation dCBT-I is effective in reducing the severity of symptoms associated with the insomnia disorder. These findings support the widespread dissemination of dCBT-I. Future research is needed to identify the moderators of response and to improve targeting.en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.titleEffects of digital cognitive behavioural therapy for insomnia on insomnia severity: a large-scale randomised controlled trialen_US
dc.typeJournal articleen_US
dc.rights.holderCopyright 2020 The Authorsen_US
dc.source.journalThe Lancet Digital Healthen_US
dc.relation.projectNIFU: 90061500en_US
dc.relation.projectNorges forskningsråd: 239985en_US
dc.identifier.citationThe Lancet Digital Health. 2020, 2 (8), e397-e406en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal